Spesolimab GPP flare prevention appraisal terminated, no evidence
Summary
NICE has terminated its appraisal of subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalized pustular psoriasis flares in patients 12 years and older. The termination occurred because the manufacturer did not provide an evidence submission, leaving NICE unable to assess clinical effectiveness or cost-effectiveness. No NHS funding guidance will be issued for this indication.
What changed
NICE has terminated appraisal TA1144 for subcutaneous spesolimab 1-ml formulation in generalized pustular psoriasis flare prevention. The company withdrew from the process by failing to provide an evidence submission, preventing NICE from conducting its standard health technology assessment.\n\nHealthcare providers treating GPP patients will not receive NHS commissioning guidance on this spesolimab formulation. Pharmaceutical companies considering NICE submissions should ensure timely evidence packages to avoid appraisal termination, which delays patient access to potentially beneficial treatments.
What to do next
- Monitor for updates if the manufacturer decides to submit evidence for future appraisal
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
- Technology appraisal
- TA1144
- Published:
08 April 2026
Overview
NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the company did not provide an evidence submission.
Last reviewed: 08 April 2026
Next review: We will review this decision if the company decides to make a submission.
Guidance development process
Related changes
Get daily alerts for NICE Technology Appraisals
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NICE.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when NICE Technology Appraisals publishes new changes.